Clinical trials: Brain Injury Traumatic Moderate
- Condition Brain Injury Traumatic Moderate
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Traumatic Brain Injury
A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.
A Randomized, Double Blind, Placebo Controlled, Phase 2 Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple I.V.
- Trial name
- NCT00735085
- Testing
- SLV334
- Where
- 14 sites in United States, Israel and 2 more
- Volunteers
- 57 people
- Sponsor
- Abbott Products